Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention

International Journal of Obesity

Volumn 31, Issue 1, 2007, Pages 15-22

  Fu, J F ^a   Liang, L ^a   Zou, C C ^a   Hong, F ^a   Wang, C L ^a   Wang, X M ^a   Zhao, Z Y ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adiponectin; Children and adolescents; Metabolic syndrome; Metformin

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

ADOLESCENT; APPETITE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHINA; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; EVALUATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINAL DYSMOTILITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATIENT SAFETY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADIPONECTIN; ADOLESCENT; BODY MASS INDEX; BODY SIZE; CHILD; CHINA; EXERCISE THERAPY; FEMALE; FOOD HABITS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIFE STYLE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; METFORMIN; OBESITY; PREVALENCE; TREATMENT OUTCOME;

EID: 33845809235     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803453     Document Type: Article

References (37)

1. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-436.
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
3. Tong W, Lai H, Yang C, Ren S, Dai S, Lai S. Age, gender and metabolic syndrome-related coronary heart disease in U.S adults. Int J Cardiol 2005; 104: 288-291.
4. Kaur H, Hyder ML, Poston WS. Childhood overweight: an expanding problem. Treat Endocrinol 2003; 2: 375-388. Review.
5. Kohen-Avramoglu R, Theriault A, Adeli K. Emergency of the metabolism syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem 2003; 36: 413-420.
6. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Yet al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
7. Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K. Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 2003; 26: 705-710.
8. Yohei O, Toru K, Keisuke N, Makoto H, Yukie T, Makoto U. Useful of serum adiponectin level as a diagnostic marker of metabolic syndrome in obese Japanese children. Hypertens Res 2005; 28: 51-57.
9. Bestermann W, Houston MC, Basile J, Egan B, Ferrario CM, Lackland D et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005; 329: 292-305. Review.
10. Ya-mei H, Zai-fang J. Practical Pediatric Textbook of Fu-tang Zhu 7th edn. People's Hygienic Publish Society: Beijing, 2000. pp. 27-30 553,1414, 2047, 2687.
11. Metabolic syndrome study group of Chinese Diabetes Association. Proposal of metabolic syndrome by Chinese Diabetes Association. Chinese J Diabetes 2004; 12: 156-161.
12. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998; 15: 539-553.
14. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
15. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 2005; 17: 636-641.
16. Sung RY, Tong PC, Yu CW, Lau PW, Mok GT, Yam MC et al. High prevalence of insulin resistance and metabolic syndrome in overweight/obese preadolescent Hong Kong Chinese children aged 9-12 years. Diabetes Care 2003; 26: 250-251.
17. Yoshinaga M, Tanaka S, Shimago A, Sameshima K, Nishi J, Nomura Y et al. Metabolic syndrome in overweight and obese Japanese children. Obese Res 2005; 13: 1135-1140.
18. Cook S,WeitzmanM, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157: 821-827.
19. Otto Buczkowska E. Insulin resistance and hyperinsulinemia - risk factors of the metabolic syndrome in the pubertal population. Endokrynol Diabetol Chor Przemiany MateriiWieku Rozw 2005; 11: 109-114.
20. Woo JG, Dolan LM, Daniels SR, Goodman E, Martin LJ. Adolescent sex differences in adiponectin are conditional on pubertal development and adiposity. Obes res 2005; 13: 2095-2101.
21. Wang C-L, Liang L, Fu J-F, Hong F. Comparison of methods to detect insulin resistance in obese children and adolescents. J Zhejiang Univ: Med Sci 2005; 34: 316-319.
22. Yeckel CW,Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004; 89: 1096-1101.
23. Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004; 89: 4053-4061.
24. Matsuzawa Y. Adipocytokines and metabolic syndrome. Semin Vasc Med 2005; 5: 34-39. Review.
25. Nemet D, Wang P, Funahashi T, Matsuzawa Y, Tanaka S, Engelman L et al. Adipocytokines, body composition, and fitness in children. Pediatr Res 2003; 53: 148-152.
26. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 2003; 11: 1072-1079.
27. Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, Kumanyika S et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005; 111: 1999-2012.
28. Kobayashi K. Adipokines: therapeutic targets for metabolic syndrome. Curr Drug Targets 2005; 6: 525-529. Review.
29. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21: 80-89.
30. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S et al., Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619.
31. Benavides S, Striet J, Germak J, Nahata MC. Efficacy and safety of hypoglycemic drugs in children with type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 803-809.
32. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002; 25: 89-94.
33. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
34. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-146.
35. Santana LF, de Sa MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol 2004; 19: 88-96.
36. Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003; 63: 1879-1894. Review.
37. Mehnert H. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S259-S264. Review.